Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Mon, Oct 21
Tue, Oct 22
Wed, Oct 23
Poster Schedule
Type here to filter the list
Wednesday, October 23, 2024
9:30 AM – 10:30 AM
MT
(W0930-01-01) Are Amorphous Drugs More Compressible Than Their Crystalline Counterparts?
Favorite
9:30 AM – 10:30 AM
MT
(W0930-01-02) Transdermal Delivery of Ultradeformable Cationic Liposomes Complexed with microRNA Prevents Transformation of Melanocytes to Melanoma
Favorite
9:30 AM – 10:30 AM
MT
(W0930-01-03) Optimization of Phospholipid Based Nano Drug Delivery System of Osimertinib - An In Vitro Drug Release, Ex Vivo Permeability Study
Favorite
9:30 AM – 10:30 AM
MT
(W0930-01-04) Optimizing Drum Selection for Volumetric-Based Capsule Filling: A Mechanistic Model for Lactose-Based Formulations
Favorite
9:30 AM – 10:30 AM
MT
(W0930-01-05) Oral Targeting of Sensitive Microbiome: A Case from Development of Functional Coated Capsule to Clinical Trial Phase 1b
Favorite
9:30 AM – 10:30 AM
MT
(W0930-01-06) Application of Acid-Base Supersolubilization (ABS) Principle to Increase Aqueous Solubility of Weakly Acidic Drug Indomethacin and Its Dissolution from ASD Prepared by Hot-Melt Extrusion
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-07) Revolutionising Microneedle-Based Transdermal Delivery: A Colourful Approach to Efficiency Feedback and User Navigation
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-08) Lumbar Intrathecal Infusion of an siRNA Formulation via Cannulation in Rats Demonstrated Comparable Tissue Distributions and Improved Animal Response as Comparing to Non-Cannulated Free Hand Method
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-09) Toxicokinetics of MEB-1170, a mu-Opioid Receptor Agonist, in Dogs in a 28-Day Oral Toxicity Study
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-10) Evaluation of the Disposition and Absolute Bioavailability of Imlunestrant in Healthy Volunteers
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-11) VLX-1005 Multiple Ascending Dose Pharmacokinetics
Favorite
9:30 AM – 10:30 AM
MT
(W0930-02-12) Oral Tolerance Mediated by Phosphatidylserine Containing Lipid Nanoparticle
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-13) Evaluating the Feasibility of Lyophilization for Oral Formulation Development of Monoclonal Antibodies (mAbs)
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-14) A Journey Through the Development of Cannabidiol Solid Oral Dosage Forms: Balancing API Loading, Physico-Chemical Stability and In Vivo Pharmacokinetic Performance
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-15) Spray Drying of Directly Compressible Amorphous Solid Dispersions (ASDs): Comparison of Different Polymers
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-16) Comparative Bioavailability Study of Jaspine B: Impact of Nano-Liposomal Drug Delivery System on Pharmacokinetics
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-17) Molecular Structure-Based Predictions of Amorphous Solid Dispersion Formation Are More Accurate When Appropriate Solvent and Faster Solidification Kinetics Are Used
Favorite
9:30 AM – 10:30 AM
MT
(W0930-03-18) In Vitro Release Method Development for Onivyde
®
Using Agilent NanoDis
®
System
Favorite
9:30 AM – 10:30 AM
MT
(W0930-04-19) Quantitative Phase Imaging for Evaluation of the Radioprotective Effects of Synthetic Glycosaminoglycans on Immune Cells
Favorite
9:30 AM – 10:30 AM
MT
(W0930-04-20) Kruppel-Like Factor 2 (KLF2) Reduces Parameters of Coronavirus Disease-Related Pathogenesis
Favorite
9:30 AM – 10:30 AM
MT
(W0930-04-21) Combination Therapy with Carboplatin and miR-5193/149-5p Mimics Against PD-L1 and FOXM1 Axes Loaded in NK-EVs Show Synergistic Effects in Two EGFR-TKI-Resistant (PDX and H1975R) Lung Tumor Models
Favorite
9:30 AM – 10:30 AM
MT
(W0930-04-23) Three Dimensional Industrial DNA Nanorobot as a Functional Drug Delivery System
Favorite
9:30 AM – 10:30 AM
MT
(W0930-04-24) Kidney Metabolomics Demonstrated the Energy Supply Upregulation by
Radix Aconiti Lateralis
Preparations in Rats
Favorite
9:30 AM – 10:30 AM
MT
(W0930-05-26) Preclinical Development of Long Acting Injectables for Delivery of Targeted Protein Degraders
Favorite
9:30 AM – 10:30 AM
MT
(W0930-05-27) Compaction Simulation as a Risk Mitigation Strategy for Dual Sourcing on Commercial Drug Products
Favorite
9:30 AM – 10:30 AM
MT
(W0930-05-28) Enhancing Oral Delivery of Alginate-Encapsulated Probiotics: The Novel and Versatile Role of Casein as an Excipient
Favorite
9:30 AM – 10:30 AM
MT
(W0930-05-29) Comparative Study of Mold Casting and Vacuum Compression Molding Techniques for Fabricating Drug-Loaded Microneedle Arrays: Precision, Drug Loading, and Performance Evaluation
Favorite
9:30 AM – 10:30 AM
MT
(W0930-05-30) Broad Applicability of a Model for Predicting Tabletability of Mixtures from Those of Individual Components
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-31) Simultaneous Quantification of Multiple ADC Component Concentrations and DAR Profiling with One Aliquot of Plasma in NHP Toxicology Study by Hybrid LC-MS
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-32) A Sensitive Method for the Detection and Quantitation of Nalmefene in Human Plasma Samples for Pharmacokinetic Analysis
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-33) Receptor Occupancy Assay Development Challenges for Rare Targets of Bispecific Drugs
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-34) Validation of an LCMS Hybrid Assay with EVOSEP Cleanup for the Quantitation of Islet Amyloid Polypeptide in Human Plasma
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-35) Development of Rabbit Anti-Mertansine (DM1) Monoclonal Antibodies
Favorite
9:30 AM – 10:30 AM
MT
(W0930-06-36) ICH M10 Bioanalytical Method Validation for Quantitation of Ketorolac in Human Vitreous and Aqueous Humor using Human Plasma as a Surrogate Matrix
Favorite
9:30 AM – 10:30 AM
MT
(W0930-07-37) Nanoparticle Development for Systemic Delivery of Resiquimod to Reactivate Immunosuppressive Tumor Microenvironment
Favorite
9:30 AM – 10:30 AM
MT
(W0930-07-38) An Efficient Strategy to Overcome Poor Flow and Compressibility Issues of Lamivudine for a Robust Tablet Formulation Using a Coprocessed Excipient
Favorite
9:30 AM – 10:30 AM
MT
(W0930-07-39) Development and Characterization of Cannabidiol and Rho Kinase Inhibitor Combination Formulations for Ophthalmic Use
Favorite
9:30 AM – 10:30 AM
MT
(W0930-07-41) Evaluation of Plasticizer and Stabilizer Effect on Drug Release Profiles of Taste-Masked Vardenafil MUPS ODT
Favorite
9:30 AM – 10:30 AM
MT
(W0930-09-48) Impact of Excipient Purity on the Stability of Chemotherapy Drugs
Favorite
9:30 AM – 10:30 AM
MT
(W0930-09-49) Biopharma Mixing Scale-Up: Small-Scale and Computational Studies
Favorite
9:30 AM – 10:30 AM
MT
(W0930-09-50) Determining the Most Suitable Gelling Agent for Topical Semi-Solid Formulation Development- An Investigation into the Physical Robustness of Various Gelling Agents
Favorite
9:30 AM – 10:30 AM
MT
(W0930-09-51) Evaluating Formulation Platforms for Poorly Soluble APIs to Mimic PROTACs
Favorite
9:30 AM – 10:30 AM
MT
(W0930-09-52) Uncovering the Role of Risperidone Attributes on the In Vitro Release and Formation of In Situ Forming Implants
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-54) Comparative In Vitro Release and Clinical Pharmacokinetics of Leuprorelin Depot 3.75mg, a One-Month Sustained-Release Formulation of Leuprorelin Acetate
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-55) Development of a Sensitive, Drug Tolerant Total Antibody Assay for the Detection of Antibodies against a Novel Capsid AAVPRV in Human Serum and CSF
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-56) Leveraging Cross-Species Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling to Drive Discovery Efforts of a Novel Protein Degrader
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-57) Orforglipron Weight Loss and Nausea Accurately Simulated with OBESITYsym
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-58) Translational Research to Facilitate Development of Novel Therapeutic Combination of Letrozole with a CDK 4/6 Inhibitor Ribociclib for the Treatment of Glioblastoma
Favorite
9:30 AM – 10:30 AM
MT
(W0930-10-59) Matrix Comparability Assessment between 3.2% Sodium Citrate and 3.8% Sodium Citrate Human Plasma in PK and ADA Assays
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-60) Case Study Approach of an Excipient Compaction Assessment to Support Dual Sourcing
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-61) Quantitative and Qualitative Analysis of Lipids and Cholesterol Derivatives in SMOF Lipids 20% Intravenous Lipid Emulsion
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-62) Quantification of Novel Racemic Compound of Guaifenesin in Commercial Conglomerate Material Using Powder X-ray Diffraction
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-63) Improving Adhesion Evaluation of Transdermal Rotigotine Patches: Utilizing Skin-Mimicking Substrates for Accurate Assessment
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-64) Developing an Assessment Framework, Items, and Expert Reviews for an Educational Instrument for the Proper Use of the USP/NF Pharmacopeia
Favorite
9:30 AM – 10:30 AM
MT
(W0930-11-65) Transfer of a Low Dose Formulation from Batch to Continuous Manufacturing: High-Shear Wet Granulation to Continuous Twin-Screw Wet Granulation
Favorite
10:30 AM – 11:30 AM
MT
(W1030-01-01) Nitrosamine Mitigation Case Study: The Importance of Utilizing a Multi-Pronged Approach to Reduce Impurities
Favorite
10:30 AM – 11:30 AM
MT
(W1030-01-02) Harnessing the Potential of Self-Assembled Hyaluronic Acid Nanoparticles for Tumor Targeted Co-Delivery of Betulinic Acid and Paclitaxel
Favorite
10:30 AM – 11:30 AM
MT
(W1030-01-04) In Vitro Characterization and In Vivo Efficacy Study of a 2nd Generation Synthetic Lung Surfactant (SLS) Excipient Enhanced Growth (EEG) Dry Powder Formulation and Device
Favorite
10:30 AM – 11:30 AM
MT
(W1030-01-05) Sustainable Development of a Nanosystem for the Co-encapsulation of Apigenin and Curcumin for Pharmaceutical Applications
Favorite
10:30 AM – 11:30 AM
MT
(W1030-01-06) Facile and Tunable Nanoparticle Delivery with Granular Hydrogels
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-07) Determination of the Concentration of Monoclonal Antibodies (Mab) Drug in Human Serum Using an Enzyme-Linked Immunosorbent Assay (ELISA)
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-08) Distribution of Standard-of-Care Antituberculosis Drugs in Cynomolgus Macaque Lungs
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-09) Machine Learning-Based Rational Design of Inorganic Nanoparticles for Improved Safety in Biomedical Applications
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-10) Development of a Predictive Model for Vancomycin-Associated Nephrotoxicity Using the Area under the Concentration-Time Curve of Vancomycin: A Machine Learning Analysis
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-11) Immunotoxicity of Silica Nanoparticles as a Function of Physicochemical Properties
Favorite
10:30 AM – 11:30 AM
MT
(W1030-02-12) Comparative Detection of Pre-existing Anti‑AAV8 Antibodies in Normal Human Serum by a Total Antibody Assay Versus a Transduction Inhibition Assay
Favorite
10:30 AM – 11:30 AM
MT
(W1030-03-13) Role of Polyethylene Glycol and Propylene Glycol in Modulating the Spreadability and 3-D Structure of a Carbomer Based Nasal Gel
Favorite
10:30 AM – 11:30 AM
MT
(W1030-03-15) The Evaluation of Methacrylic Acid Copolymer as a Direct Compressible Excipient for Erosion Based Sustained Release Matrix Tablets
Favorite
10:30 AM – 11:30 AM
MT
(W1030-03-16) Predicting the Aggregation Behavior of Liposomes Using Thermal Analysis
Favorite
10:30 AM – 11:30 AM
MT
(W1030-03-17) Amorphous Stabilization of BCS II Drugs Using Mesoporous Silica
Favorite
10:30 AM – 11:30 AM
MT
(W1030-03-18) Exploring the Potential of Inhaled Clofazimine Liposomes for Mesothelioma Treatment
Favorite
10:30 AM – 11:30 AM
MT
(W1030-04-19) Beyond Voltage-Gated Sodium Channel (Na
v
1.7): Exploring the Dual Role of GX201 and Sulfamethoxazole in Itch Management
Favorite
10:30 AM – 11:30 AM
MT
(W1030-04-20) Combination of Multivalent DR5 Receptor Clustering Agonists and Histone Deacetylase Inhibitors for Treatment of Colon Cancer
Favorite
10:30 AM – 11:30 AM
MT
(W1030-04-21) Computational Pharmaceutics Approaches to Guide Lipid Based Formulation Development: How Data Mining Can Improve the Process
Favorite
10:30 AM – 11:30 AM
MT
(W1030-04-22) Antimicrobial Effects of S-nitrosothiols on
Mycobacterium abscessus
Biofilms
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-25) Targeted Peptide Dual Drug Conjugate for the Treatment of Glioblastoma
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-26) Transdermal Lamivudine Deep Eutectic Systems for the Long-Term Management of Pediatric Hepatitis B Virus and HIV Infections
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-27) Comparison of Two Self-Nanoemulsifying Drug Delivery Systems Using Different Solidification Techniques for Enhanced Solubility and Oral Bioavailability of Poorly Water-Soluble Celecoxib
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-28) Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC)
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-29) Topical Cream Formulation of Integrated Stress Response Inhibitor (ISRIB) for the Potential Treatment of Chemical Warfare Skin Injury: Effect of Chemical Enhancers, Concentration, and pH
Favorite
10:30 AM – 11:30 AM
MT
(W1030-05-30) One Like the Other? A Novel In Vitro Release Method to Ensure Proper Drug Release of Extended-Release Mini-Tablets for Paediatric Use
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-31) Comparison of the Performance of Luminex-Based and MSD-Based Immunogenicity Assays for Multivalent HPV Vaccines
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-32) An Electrochemiluminescence (ECL)-Based Assay for the Specific Detection of Neutralizing Anti-CAEL-01 Antibodies in Human Serum with a Pre-Treatment Procedure to Eliminate Therapeutic Drug
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-33) Development of Sensitive Free and Total Assays for the Quantification of Soluble CD200R1 in Human Plasma Samples to Assess Drug-Target Engagement
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-34) Stabilization of a Therapeutic Peptide for a Quantitative ECLIA Assay
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-35) Pharmacologically Active Drug Metabolites: Impact on Drug Discovery
Favorite
10:30 AM – 11:30 AM
MT
(W1030-06-36) Development of a Rapid, High Throughput Quantitative Bioanalysis of Conjugated Payloads of Protease-Cleavable Antibody-Drug Conjugate (ADC) in Rat Serum Using Automated Immunocapture Based UPLC-MS/MS
Favorite
10:30 AM – 11:30 AM
MT
(W1030-07-37) Formulation with Hydroxypropyl ß-Cyclodextrin Preserves the Potency of Adenovirus Vectors Under Heat and Light Stress
Favorite
10:30 AM – 11:30 AM
MT
(W1030-07-38) Development of Targeted Nanovehicles to Deliver Biomolecules to Cerebrovascular Endothelium
Favorite
10:30 AM – 11:30 AM
MT
(W1030-07-39) Mesenchymal Stem Cell-Based Combination Therapy for Enhanced Efficacy Against Patient-Derived Lung Cancer Xenograft Model
Favorite
10:30 AM – 11:30 AM
MT
(W1030-07-40) Using Gravitational Force to Determine the Minimum Concentration of Various Gelling Agents Needed to Maintain Homogeneity of Micronized API in Suspension
Favorite
10:30 AM – 11:30 AM
MT
(W1030-07-41) Phage-Antibiotic Loaded Coaxial Electrospun Fibres for Antibiotic Resistant Wound Infections
Favorite
10:30 AM – 11:30 AM
MT
(W1030-09-48) Comparison of Plant and Animal Sources of Squalene as Adjuvants for Use in Vaccine Applications
Favorite
10:30 AM – 11:30 AM
MT
(W1030-09-50) Development of Colon-Targeting UniORV Containing Salazosulfapyridine Composed of Chitosan/Alginate-Based Matrix
Favorite
10:30 AM – 11:30 AM
MT
(W1030-09-51) Early-Phase Form Screening of Solubility-Limited Drugs Via In Vitro Characterization and In Silico Modeling
Favorite
10:30 AM – 11:30 AM
MT
(W1030-09-52) Development of L-dopa-Loaded Nanofiber for Transbuccal Drug Delivery
Favorite
10:30 AM – 11:30 AM
MT
(W1030-10-55) Optimizing Tablet Formulation through Integrated Use of Digital Formulation Tools and Compaction Simulation
Favorite
10:30 AM – 11:30 AM
MT
(W1030-10-56) Validation and Application of an LC-MS/MS Method to Evaluate In Vitro Permeation of Naloxone Nasal Spray Using Artificial Substrate
Favorite
10:30 AM – 11:30 AM
MT
(W1030-10-57) The Effect of Food Vehicle on In Vitro Performance of Mini-Tablets Formulation
Favorite
10:30 AM – 11:30 AM
MT
(W1030-10-58) Next-Generation Bio-Inert HPLC System for Enhanced Analysis of Biotherapeutics
Favorite
10:30 AM – 11:30 AM
MT
(W1030-10-59) Optimization of Assay Method for a Drug with Two pKa
Favorite
10:30 AM – 11:30 AM
MT
(W1030-11-60) Canada and the World: A Comparative Global Regulatory and Quality Variability Study of Melatonin Health Products
Favorite
10:30 AM – 11:30 AM
MT
(W1030-11-61) Sending Ritonavir to Space and Back – Drug Development Enabled by Specially Designed Hardware to Perform in Microgravity
Favorite
10:30 AM – 11:30 AM
MT
(W1030-11-62) Production of Drug Nanocrystals Using a Cost-Effective Miniaturised Media Milling Approach
Favorite
10:30 AM – 11:30 AM
MT
(W1030-11-63) Crystalline Craftsmanship: Controlling Surface Roughness of Spray-Freeze-Dried Particles
Favorite
10:30 AM – 11:30 AM
MT
(W1030-11-65) Vicious Variability: Capillary Isoelectric Focusing Method Performance Issues with Non-Detergent Sulfobetaine 211 as an Additive
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-01) Development of an Intraocular In Situ-Forming Implant of a Novel Compound to Target the Retina in a Rabbit Model
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-02) Bioequivalence Approaches Utilized in Generic Drug Applications for Topical Drug Products Applied to the Skin
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-03) Simulation of Variable Fasted Gastric Motility and pH as a Key to Understand Contrasting Properties of Immediate Release Pellet-Filled Capsules and Bare Pellets
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-04) Predicting Hydroxypropyl Methylcellulose-Controlled Release Matrix Performance with Powder Dissolution Temperature
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-05) Preformulation Studies to Guide the Processing of Triamcinolone Acetonide by Hot-Melt Extrusion
Favorite
11:30 AM – 12:30 PM
MT
(W1130-01-06) DoE-Enabled Development of Osimertinib-Encapsulated PLGA Nanoparticles for the Treatment of Non-Small Cell Lung Cancer
Favorite
11:30 AM – 12:30 PM
MT
(W1130-02-07) Development and Verification of a Physiologically-Based Pharmacokinetic (PBPK) Model for Vaginal Administration of Progesterone Ring and Gel Formulations
Favorite
11:30 AM – 12:30 PM
MT
(W1130-02-09) Maternal Exposure to Kratom Alkaloids: A Comparative Pharmacokinetic Study of Various Kratom Preparations in Pregnant Rats
Favorite
11:30 AM – 12:30 PM
MT
(W1130-02-10) The Advantage and Disadvantage of In Vivo Predictive Dissolution Profiles of BCS Class II Drugs Generated by a Transfer Method and Compendial Method with Different Buffer Species
Favorite
11:30 AM – 12:30 PM
MT
(W1130-02-11) Having Appropriate Critical Reagents Can Make Bi-Specific Drug Anti-Drug Antibody Assays Less Challenging and Easy to Specifically Quantify
Favorite
11:30 AM – 12:30 PM
MT
(W1130-02-12) Virtual Bioequivalence (VBE) Outcome May Depend on Choice of Dissolution Inputs in Physiologically Based Pharmacokinetic Modelling
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-13) Powerful Tools for Precise Engineering of Viatel
TM
Diblock Nanoparticle Size: Polymer and Solvent Structure
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-14) Microarray Patches with Cyclodextrin-Carvedilol Complex for Heart Failure Treatment
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-15) A Biorelevant In Vitro Methodology for Assessing the Efficiency and Safety of Activated Charcoal in the Management of Drug-Induced Intestinal Dysbiosis
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-16) Development of Novel Local Anesthetics-Clay Composite Formulations to Improve Stability and Reduce Onset Time
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-17) Re-engineering of Lipid Nanoparticles Using Ionic Liquids for Brain Drug Delivery
Favorite
11:30 AM – 12:30 PM
MT
(W1130-03-18) Formulation Development of Famotidine Floating Tablets Using Hot-Melt Extrusion and 3D Printing Techniques
Favorite
11:30 AM – 12:30 PM
MT
(W1130-04-19) GSH-Dependent Inhibition of Multidrug Resistance-Associated Protein 1 (MRP1) by ZW-1226
Favorite
11:30 AM – 12:30 PM
MT
(W1130-04-20) A Nano-Emulsion-Based Formulation of Sorafenib for Oral Bioavailability Enhancement and Repurposing against Non-small Cell Lung Cancer (NSCLC)
Favorite
11:30 AM – 12:30 PM
MT
(W1130-04-21) Identification of Potential Drug Combinations against BRAF V600E,
p53 R273H HT-29 Colon Cancer Cells With and Without BRCA1 Knocked Down
Favorite
11:30 AM – 12:30 PM
MT
(W1130-04-22) Conformational Analysis of Alkyl/Aryl-α-
O
-Glycosides Using Isothermal Calorimetry: Stereo-Electronic Effects vs Hydrophobic Effect
Favorite
11:30 AM – 12:30 PM
MT
(W1130-04-23) Implementation of a Semi-Automated Bead Extraction Procedure during Analyte Purification for High Throughput Immunogenicity Assays
Favorite
11:30 AM – 12:30 PM
MT
(W1130-07-37) Drug Product Development Approaches to Overcome Stability Challenges of Antibody Drug Conjugates (ADCs)
Favorite
11:30 AM – 12:30 PM
MT
(W1130-07-38) Sustainable Alternatives to Petroleum-Derived Excipients in Topical Creams
Favorite
11:30 AM – 12:30 PM
MT
(W1130-07-39) Investigating ISFIs with PLGA as Sustained Release Formulations for the Urinary Bladder
Favorite
11:30 AM – 12:30 PM
MT
(W1130-07-40) Integrating Bioaccessibility Data from the Tiny-TIMsg into a Physiologically Based Biopharmaceutics Model (PBBM) of a BCS Class IV Compound to Predict Pharmacokinetic (PK) Performance
Favorite
11:30 AM – 12:30 PM
MT
(W1130-07-41) Biorelevant Dissolution Testing for Protein-Based Amorphous Solid Dispersions: Improving In Vitro Formulation Ranking
Favorite
11:30 AM – 12:30 PM
MT
(W1130-09-48) Comparing the Performance of Metronidazole Topical Gels with Variant Concentrations of Polyethylene Glycol (PEG) 400 in the Formulation
Favorite
11:30 AM – 12:30 PM
MT
(W1130-09-49) Tyrosine Kinase Inhibitor Loaded Inhalable Liposomal Formulation for Non-Small Cell Lung Cancer
Favorite
11:30 AM – 12:30 PM
MT
(W1130-09-50) Assessment of In Vitro Skin Permeation of Ruxolitinib of OPZELURA (Ruxolitinib Phosphate) Topical Cream, EQ 1.5% Base to Support a Demonstration of Bioequivalence
Favorite
11:30 AM – 12:30 PM
MT
(W1130-09-51) Development of Crystalline Linsitinib Formulations for Local Reduction of Adipose Tissue
Favorite
11:30 AM – 12:30 PM
MT
(W1130-09-52) Insights in Designing Osmotic Modified Release Delivery Platform for Solid Dispersions: Challenges and Conception
Favorite
11:30 AM – 12:30 PM
MT
(W1130-10-54) Streamlining Pharmaceutical Process Development: A User-Centric Approach to High-Throughput Analysis
Favorite
11:30 AM – 12:30 PM
MT
(W1130-10-55) Improving Sensitivity and Accuracy in Nitrite Measurement in Hydroxypropyl Methylcellulose
Favorite
11:30 AM – 12:30 PM
MT
(W1130-10-56) Mechanistic Evaluation of Microstructure and Performance Attributes of Medicated Topical Shampoos
Favorite
11:30 AM – 12:30 PM
MT
(W1130-10-57) Assessing Topical Dosage Form Manufacturing Methods and Their Impact on Globule Microstructure with Non-Invasive Micro-CT Analysis
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-60) Using Cryo-TEM to Characterize Structural Details of LNPs During Manufacturing
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-61) Forced Degradation of Cell-Based Therapeutic Products Using Various Stresses and Use of Flow Imaging Microscopy for Identification of Damaged Cells and Cell Debris
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-62) Evaluation of Ice Nucleation/Freezing Phenomenon for a Monoclonal Antibody Drug Product Solution in Primary Container Closure Systems Using a Thermal Cycling Chamber
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-63) A New Shear Protectant: Introducing Kolliphor
®
P188 Cell Culture
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-64) Reverse Engineering of the Sublocade
®
Buprenorphine In Situ Forming Implant
Favorite
11:30 AM – 12:30 PM
MT
(W1130-11-65) Engineering Spray Dried Protein Particles to Enable Subcutaneous Injection of High Concentration Protein Suspensions
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-01) Understanding the Role of Acidic pH Modifiers in Achieving pH-Independent Release from Extended-Release Matrix Tablets of Weakly Basic Drugs
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-02) Novel Use of Excised Bovine Stomach to Study Mucoadhesive and Rheological Synergism Properties of Gastro-Retentive Antacid Formulations
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-03) Cellular Uptake of Bare and Corona Coated PEO-b-PCL and PEO-b-PBCL Micelles by HCT116 and SW620 Cell Lines
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-04) A Hybrid Mechanistic Model for Predicting Milling Performance of Roller Compacted Ribbons
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-05) Vacuum Compression Molding: A Novel Method to Fabricate Drug-Loaded Microneedles for Three-Day Transdermal Delivery of Palonosetron Hydrochloride
Favorite
12:30 PM – 1:30 PM
MT
(W1230-01-06) Peptide Conjugated Hypoxia-Responsive Nanoparticles to Decrease Triple-Negative Breast Cancer Stemness in a Patient-Derived Xenograft Mice Model
Favorite
12:30 PM – 1:30 PM
MT
(W1230-02-07) EpiScreen®2.0 Time Course Assay: A Sensitive and Data Rich Tool for Pre-Clinical Immunogenicity Testing of Biologics
Favorite
12:30 PM – 1:30 PM
MT
(W1230-02-08) Multiplexed Assays for Detection of IgG Antibodies against AAV Serotypes
Favorite
12:30 PM – 1:30 PM
MT
(W1230-02-10) Post-Complete Response Letter Scientific Meeting Requests: Key Takeaways from Case Studies
Favorite
12:30 PM – 1:30 PM
MT
(W1230-02-11) Risk Assessment for Extrapolation of Bioequivalence Conclusion from a Male-Only Study Population to the General Population
Favorite
12:30 PM – 1:30 PM
MT
(W1230-02-12) Translational PK/PD and First-in-Human Dose Selection of a Monoclonal Antibody Targeting a Membrane Protein
Favorite
12:30 PM – 1:30 PM
MT
(W1230-03-14) Impact of Lubricant on Functional Tablet Coatings Containing Pectin
Favorite
12:30 PM – 1:30 PM
MT
(W1230-03-15) Preparation of Lurasidone Hydrochloride Nanoparticles and Enhanced Bioavailability
Favorite
12:30 PM – 1:30 PM
MT
(W1230-03-16) Vaccination Against Influenza Using Fast Acting 3D Printed Oral Dissolving Films as a Delivery System
Favorite
12:30 PM – 1:30 PM
MT
(W1230-03-17) Optimizing the Process Parameters for Utilizing Hot-Melt Extrusion Technology in the Development of Cannabidiol Nano-Structured Lipid Carriers
Favorite
12:30 PM – 1:30 PM
MT
(W1230-03-18) Harnessing Albumin-Anchored BRD4 PROTAC Nanoliposomes for Selective and Targeted Degradation in Pancreatic Ductal Adenocarcinoma
Favorite
12:30 PM – 1:30 PM
MT
(W1230-04-19) Explainable Artificial Intelligence (XAI) for Generation of Library of Novel Potential Acetylcholinesterase Inhibitors
Favorite
12:30 PM – 1:30 PM
MT
(W1230-04-21) Assessment of Various
Lactobacillus Spp
as Potential Candidate for Treatment of Bacterial Vaginosis
Favorite
12:30 PM – 1:30 PM
MT
(W1230-04-22) Assessment of High Throughput Salt Screening Methodologies with Zwitterionic Compounds
Favorite
12:30 PM – 1:30 PM
MT
(W1230-04-24) Disruptions in Glucose and Amyloid-Beta Transport in Mouse Models Manifesting Metabolic Syndrome
Favorite
12:30 PM – 1:30 PM
MT
(W1230-07-37) Hydroxypropyl Beta-Cyclodextrin as a Multifunctional Excipient for Downstream Processing and Formulation of Monoclonal Antibodies
Favorite
12:30 PM – 1:30 PM
MT
(W1230-07-38) Ethanol Solubility of Rate Controlling Polymer in Modified Release Formulation Can Impact Alcohol Dose Dumping: An Assessment Through Principal Component Analysis
Favorite
12:30 PM – 1:30 PM
MT
(W1230-07-39) Lipid Nanoparticles Particle Size Control: Effect of Buffer and Linear vs Circular mRNA
Favorite
12:30 PM – 1:30 PM
MT
(W1230-07-40) Expanding the Design Space of Swellable Core Technology (SCT) for Delivery of Higher Doses and Patient Centric Dosage Form
Favorite
12:30 PM – 1:30 PM
MT
(W1230-07-41) Novel Inter-Polymer Complexes in the Development of Spray-Dried Dispersions: A Computational and Experimental Study
Favorite
12:30 PM – 1:30 PM
MT
(W1230-09-48) Understanding the Influence of Occlusion on Oxybutynin Permeation from a Transdermal Gel Deposited Film Using IVPT
Favorite
12:30 PM – 1:30 PM
MT
(W1230-09-49) Optimization of Ocular Mini Tablet Formulations: A Comparative Study of 3D FDM Printing and Vacuum Compression Molding Methods for Sustained Drug Release
Favorite
12:30 PM – 1:30 PM
MT
(W1230-09-50) Preparation and Characterization of an Ultraflexible Liposomal Gel for Transdermal Delivery of a Novel Pan-RAS Inhibitor for Melanoma
Favorite
12:30 PM – 1:30 PM
MT
(W1230-09-51) A Mucoadhesive Composition for Pulmonary Delivery of mRNA Lipid Nanoparticles
Favorite
12:30 PM – 1:30 PM
MT
(W1230-09-52) Using PBPK to Establish In Vitro In Vivo Relationship for Budesonide Delayed Release Oral Drug Product
Favorite
12:30 PM – 1:30 PM
MT
(W1230-10-54) Development of Robust and Customizable Zero-Order Release Push-Pull Osmotic Tablets
Favorite
12:30 PM – 1:30 PM
MT
(W1230-10-55) In Vivo Evaluation of Cocoyl Caprylocaprate on API Skin Permeation and Bioavailability
Favorite
12:30 PM – 1:30 PM
MT
(W1230-10-56) Efficient Manufacturing of Omeprazole Modified-Release Minitablets Using “All-in-One” Co-Processed Excipient and Talc-Free Aqueous Coating System
Favorite
12:30 PM – 1:30 PM
MT
(W1230-10-57) Efficient Development of High Drug-Loaded Posaconazole Tablets Enabled by Amorphous Solid Dispersion
Favorite
12:30 PM – 1:30 PM
MT
(W1230-10-58) A Stable and Scalable Gemcitabine and Paclitaxel Drug Combination Nanoparticle (DcNP) Exhibits Long-Acting Pharmacokinetics and Breast Tumor Regression in an Orthotopic 4T1 Mouse Model
Favorite
12:30 PM – 1:30 PM
MT
(W1230-11-60) Development and Validation of Analytical Methodology by Uv-Vis Spectrophotometry for D-Limonene Quantification
Favorite
12:30 PM – 1:30 PM
MT
(W1230-11-61) In Situ Monitoring of Dissolution and Crystallization Processes for Active Pharmaceutical Ingredients Using Low Frequency Raman Spectroscopy
Favorite
12:30 PM – 1:30 PM
MT
(W1230-11-63) A Novel First-in-Class 3D Printing Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious Diseases
Favorite
12:30 PM – 1:30 PM
MT
(W1230-11-64) A Comparative Study of Agitation-Induced Aggregation of Monoclonal Antibodies via Horizontal Shaking and Orbital Shaking
Favorite
12:30 PM – 1:30 PM
MT
(W1230-11-65) Effect of Lyophilization Process Parameters on the Stability of mRNA Lipid Nanoparticles (LNP)
Favorite
